NEW DELHI, India — June 21, 2026
India Bans 16 Fixed-Dose Combination Drugs with immediate effect after a scientific review concluded that several widely used drug combinations lacked therapeutic justification and could pose potential health risks to patients. The Ministry of Health and Family Welfare announced the decision under the provisions of the Drugs and Cosmetics Act, 1940, following recommendations from an expert committee constituted by the Drugs Technical Advisory Board (DTAB).
The move prohibits the manufacture, sale, distribution, and supply of 16 Fixed-Dose Combination (FDC) medicines across the country. Health authorities said the affected products were found to be irrational, medically inappropriate, or potentially harmful when assessed against current scientific and clinical standards.
What Are Fixed-Dose Combination Drugs?
Fixed-Dose Combination (FDC) medicines contain two or more active pharmaceutical ingredients combined in a fixed ratio within a single formulation. Such medicines are often designed to improve patient compliance and simplify treatment regimens.
However, health experts have long raised concerns that some FDC products available in the market may lack sufficient scientific evidence supporting their effectiveness or safety. In certain cases, combining multiple active ingredients may increase the risk of adverse effects, drug interactions, or inappropriate treatment.
According to the Health Ministry, the latest action follows a comprehensive review conducted under directions stemming from previous judicial and regulatory scrutiny of combination medicines.
Government Review Finds Several Drug Combinations Unjustified
The ministry stated that the expert panel examined numerous FDC formulations and concluded that several combinations did not have a sound therapeutic rationale. The committee reportedly found some products to be scientifically unsupported, clinically inappropriate, or potentially risky for public health.
Based on these findings, the central government exercised its powers under Section 26A of the Drugs and Cosmetics Act, 1940, to impose an immediate ban on the identified formulations.
Officials emphasized that the continued use of these products was not considered beneficial when weighed against the potential risks associated with their consumption.
List of Key Drug Combinations Banned
Among the prohibited formulations are combinations involving pain management, gastrointestinal treatment, diabetes care, and other therapeutic categories.
Some of the notable combinations banned include:
- Acetyl Salicylic Acid + Etoheptazine
- Dicyclomine + Paracetamol + Clidinium Bromide
- Gliclazide + Chromium Picolinate
- Paracetamol + Lignocaine
The government has also prohibited several antibiotic-based combinations that were found to lack adequate scientific justification.
These include:
- Amoxicillin + Serratiopeptidase
- Amoxicillin + Cloxacillin + Lactic Acid Bacillus + Serratiopeptidase
- Cefadroxil + Probenecid
- Cefuroxime + Serratiopeptidase
Medical experts have frequently cautioned against the irrational use of antibiotic combinations, warning that unnecessary or inappropriate antibiotic use can contribute to antimicrobial resistance, a growing global public health challenge.
Skincare and Aloe Vera-Based Combinations Also Restricted
The ban extends beyond pharmaceutical formulations to include certain skincare and topical products containing Aloe Vera or Aloe Extract combined with multiple ingredients.
Restricted combinations include products containing Aloe Vera alongside:
- Vitamin E
- Jojoba Oil
- Orange Oil
- Wheat Germ Oil
- Tea Tree Oil
- Allantoin
- D-Panthenol
Regulators determined that these combinations lacked sufficient evidence to justify their fixed-dose formulation status under existing standards.
Public Health and Regulatory Implications
The latest regulatory action reflects the government’s ongoing efforts to improve drug safety standards and ensure that medicines available in the Indian market meet scientific, clinical, and regulatory requirements.
Industry experts believe the decision may prompt pharmaceutical companies to reassess product portfolios and seek stronger clinical evidence for combination therapies before introducing them to the market.
Patients currently using any of the affected products are advised not to discontinue prescribed treatments without consulting a qualified healthcare professional. Physicians may recommend alternative medications where necessary.
Strengthening Drug Safety Framework
India has undertaken multiple reviews of fixed-dose combination medicines over the past decade as regulators seek to eliminate irrational drug formulations from the healthcare system. Authorities maintain that ensuring the availability of safe, effective, and evidence-based medicines remains a key public health priority.
The latest ban underscores the government’s focus on patient safety and evidence-based healthcare while reinforcing regulatory oversight of pharmaceutical products sold in the country.
